Nuvalent (NUVL) Share-based Compensation (2020 - 2026)
Nuvalent (NUVL) reported Share-based Compensation of $28.9 million for Q1 2026, up 41.71% on a YoY basis from $20.4 million in Q1 2025, and up 32.88% quarter-over-quarter from $21.7 million in Q4 2025.
Nuvalent (NUVL) Share-based Compensation (2020 - 2026) Analysis & Trends
Nuvalent has reported Share-based Compensation for 7 years, with the latest figure at $28.9 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 41.71% year-over-year to $28.9 million; the trailing twelve-month figure through Mar 2026 stood at $95.0 million (up 41.58% YoY), and the FY2025 full-year result was $86.5 million, up 42.79% from the prior year.
- Share-based Compensation for Q1 2026 stood at $28.9 million, up from $21.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $28.9 million in Q1 2026, with the low at $2.2 million in Q1 2022.
- Historically, Share-based Compensation has averaged $12.5 million across 5 years, with a median of $13.9 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 3292.31% — and 2025, when it jumped 34.68%.
- Nuvalent's Share-based Compensation stood at $3.0 million in 2022, then surged by 148.26% to $7.5 million in 2023, then surged by 115.46% to $16.1 million in 2024, then jumped by 34.68% to $21.7 million in 2025, then jumped by 32.88% to $28.9 million in 2026.
- The last three Share-based Compensation figures came in at $28.9 million (Q1 2026), $21.7 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 26.47 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 28.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.88 Mn |
| Mar 31, 2026 | 28.88 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Sep 30, 2025 | 22.31 Mn |
| Sep 30, 2025 | 22.31 Mn |
| Jun 30, 2025 | 22.07 Mn |
| Jun 30, 2025 | 22.07 Mn |
| Mar 31, 2025 | 20.38 Mn |
| Mar 31, 2025 | 20.38 Mn |
| Dec 31, 2024 | 16.14 Mn |
| Dec 31, 2024 | 16.14 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Jun 30, 2024 | 15.13 Mn |
| Jun 30, 2024 | 15.13 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Dec 31, 2023 | 7.49 Mn |
| Dec 31, 2023 | 7.49 Mn |